Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -20.67% and -99.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?